Table 2.
Effective treatments in animal models of tinnitus
| Compound | Mechanism of Action | Behavioral Model | References |
|---|---|---|---|
| Retigabine | KCNQ2-5 channel activator | GPIAS | Li et al. (48) |
| SF0034 | KCNQ2/3 channel activator | GPIAS | Kalappa et al. (47) |
| RL-81 | KCNQ 2/3 channel activator | Operant | Marinos et al. (39) |
| Vigabatrin | GABA agonist | Operant | Brozoski et al. (223) |
| NO-711 | GABA agonist | Operant | Yang et al. (38) |
| Gabapentin | GABA agonist | Operant | Bauer and Brozoski (14) |
| Infenprodil | NMDAR antagonist | Operant | Guitton and Dudai (224) |
| AM-101 | NMDAR antagonist | Operant | Bing et al. (203) |
| M8324 | GABAergic NMDAR positive allosteric modulator | GPIAS | Deng et al. (160) |
| PLX3397 | Depletes microglia, downregulates TNF-a | GPIAS | Wang et al. (96) |
NMDAR, NMDA receptor; GPIAS, gap-prepulse inhibition of acoustic startle.